



22nd MAY 2020 | Number 4

XENOTHERA NEWS

Official news bulletin for XAV-19



EDITORIAL

by Odile DUVAUX, President of XENOTHERA

This week has been dominated by a media controversy regarding the advisability of a French pharmaceutical laboratory marketing its innovations across the Atlantic. Surprising, and yet so real. Health, treatments, vaccines, and money ... it is impossible not to see something strange, even abnormal, in the emerging role of economics in the realm of healthcare. However, funding will always be sought wherever it can be found, and the United States is leading the way, which will come as no surprise to anyone. My thoughts naturally turn to the important issue of corporate social responsibility. Or how one should use one's freedom. With open eyes and without ideology, in a world that is gradually becoming multipolar. It's a challenge ...

MAIN FOCUS

Update on XAV-19 news

Looking ahead, this week closes with significant progress for XENOTHERA. The first batch of XAV-19 continues towards pharmaceutical release, the quantities are sufficient for the start of the clinical trial, which is still scheduled for late June - early July. At the same time, the details of the phase 2 clinical trial are becoming more precise, through collaborative work between clinicians and scientists; the goal is to define precisely when and to whom the treatment will be administered.





As we have made clear in our communications, XAV-19 will be intended for patients at the beginning of hospitalization, to prevent the worsening of the disease. The trial will be carried out by several hospitals in order to be able to speed up the conclusions as much as possible, which we hope will of course be favourable. Throughout the week we continue with the discreet but essential work of writing the documentation for the clinical trial authorization file. This meticulous work is carried out by the XENOTHERA teams, working on site together again.

TESTIMONY

Support of XENOTHERA

Olivier Nordon, Doctor of Medicine and expert with the APM (Association Progrès du Management), is the founder of the firm Tête Rousse Conseil. In the late 1990's, before creating the company, he was advisor to the vice-president of MEDEF, managing director of a major consulting firm and managed several SMEs.

He explains the reasons for his support for XENOTHERA and XAV-19 :

(Click on the image to go to his forum)



XAV-19 essentials

What is it? Who is it for? What technology is used? Treatment at what stage for what expectations?

Click [here](#) for a diagram explaining XAV-19.



In the press...

Click on the logos to access articles.



Find our latest press releases:

- [XENOTHERA launches support campaign to finalise treatment for coronavirus infections, including Covid-19](#)
- [LFB signs agreement with biotech XENOTHERA](#)
- [The search for Covid-19 treatments: how can the antibodies developed by the French biotech XENOTHERA help?](#)

XENOTHERA :

XENOTHERA, created in 2014, is a Nantes-based biotech company which develops “humanized” polyclonal antibodies. Their technological platform is based on dual expertise in animal genetics and a mastery of immunology. The company has a complete portfolio of products, the first of which, LIS1, an immunosuppressant for transplants, has been in clinical trials since 2019. XENOTHERA is part of the Nantes scientific, medical and academic environment and is supported by the Pays de la Loire region's Atlanpole competitiveness cluster. Since its creation, the company has raised 6 million euros in equity and has received support from the BPI. For more information go to www.xenothera.com

Follow XENOTHERA on social media :



Contact :

XENOTHERA

1 rue Vauban - 44 000 Nantes
xenothera@izsogood.co